12 Best Genomics Stocks to Invest In

Page 8 of 11

4. Prime Medicine, Inc. (NASDAQ:PRME)

Number of Hedge Fund Holders: 30  

Analysts’ Upside Potential as of December 24: 63.78%

Prime Medicine, Inc. (NASDAQ:PRME) is among the Best Genomics Stocks.

Prime Medicine, Inc. (NASDAQ:PRME) stated on December 7, 2025, that the New England Journal of Medicine has published Phase 1/2 clinical results for PM359, its experimental autologous hematopoietic stem cell therapy for p47phox chronic granulomatous condition. Prime Editing for p47-phox Chronic Granulomatous Disease is a publication that presents preliminary data from two individuals treated in a Phase 1/2 trial intended to assess safety, biological function, and initial effectiveness in both adult and pediatric participants. Prior CGD-defining problems were seen in both patients. Each had fast neutrophil engraftment, with 69% and 83% dihydrorhodamine-positive neutrophils by Day 30. Following infusion, neither patient experienced any new CGD-related problems or serious concurrent illnesses. The observed toxicities were compatible with busulfan-based conditioning, and no clinically relevant adverse events linked to PM359 were documented.

As reported by TheFly, LifeSci Capital started covering Prime Medicine, Inc. (NASDAQ:PRME) on December 23, 2025, with an Outperform rating and a $6 price target. LifeSci Capital noted that the business is creating one-and-done gene editing treatments for conditions like cystic fibrosis, Wilson’s disease, and alpha-1 antitrypsin deficiency that have an extensive unmet demand. The firm stated it is optimistic about the potential in Wilson’s disease and alpha-1 antitrypsin deficiency.

Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology business focused on providing genetic medicines to treat diseases through the use of gene editing technology, known as Prime Editing.

Page 8 of 11